Misplaced marketing Misplaced fears of off label prescription drug marketing

Journal of Consumer Marketing

Volumn 20, Issue 6, 2003, Pages 513-515

  Galloway, Chester S ^a  

^a AUBURN UNIVERSITY   (United States)

Author keywords

Drugs companies; Marketing; Marketing management; USA

Indexed keywords

EID: 0348230686     PISSN: 07363761     EISSN: None     Source Type: Journal    
DOI: 10.1108/07363760310499084     Document Type: Article

References (6)

1. Ashley, M.J., Rehm, J., Bondy, S., Single, E. and Rankin, J. (2000), “Beyond ischemic heart disease: are there other health benefits from drinking alcohol?”, Contemporary Drug Problems, Vol. 27, pp. 735-77.
2. (The) (California) Sacramento Bee (2002), “Walking a medical tightrope with few drugs tested for children, physicians rely on trial and error”, The (California) Sacramento Bee, 24 June, available at: http://infoweb.newsbank
3. DiMasi, J.D., Hansen, R.W. and Grabowski, H.G. (2003), “The price of innovation: new estimates of drug development costs”, Journal of Health Economics, Vol. 22, pp. 151-85.
4. FDA Consumer (2002), “FDA approves restricted marketing of Lotronex”, FDA Consumer, Vol. 36, July/August, p. 4.
5. Pande, A.C., Crockatt, J.G., Janney, C.A., Werth, J.L. and Tsaroucha G. (2000), “Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy”, Bipolar Disorder, No. 3, Pt. 2, 2 September, pp. 249-55.
6. Rotfeld, H.J. (2002), “Information you can't use”, Journal of Consumer Affairs, Vol. 36, Winter, pp. 299-302.